Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by
circulating autoantibodies that recognize cell surface phospholipids and phospholipid …

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence
of antiphospholipid antibodies (aPL)(lupus anticoagulant, anticardiolipin antibodies and anti …

Objective To develop recommendations for cardiovascular risk (CVR) management in gout,
vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD) …

This guidance focuses on methodological aspects of lupus anticoagulant (LA) testing, as
well as interpretation of results for clinicians. The main changes in how to test for LA …

Antiphospholipid syndrome (APS), an acquired autoimmune thrombophilia, is characterised
by thrombosis and/or pregnancy morbidity in association with persistent antiphospholipid …

Thrombotic antiphospholipid syndrome (APS) is characterised by venous, arterial and/or
small vessel thrombosis in the context of persistently positive antiphospholipid antibodies …

Background A large number of observational studies showed that patients with psoriasis
have a higher risk of cardiovascular disease (CVD), but most studies did not fully adjust for …

Background The optimal strategy for diagnosis and antithrombotic treatment of patients with
antiphospholipid syndrome (APS)–associated acute ischemic stroke (AIS), transient …

Antiphospholipid antibodies (APLAs) are primarily directed toward phospholipid-binding
proteins and are responsible for thrombotic events. APLAs include anti-β2Glycoprotein I …

Antiphospholipid syndrome (APS) is a prothrombotic autoimmune disease with
heterogeneous clinicopathological manifestations and is a well-established cause of acute …